KYTHERA Biopharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Over-Allotment Option


WESTLAKE VILLAGE, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- KYTHERA
Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced the closing of
its underwritten public offering of 2,994,793 shares of its common
stock at a price to the public of $48.00 per share for gross proceeds
of approximately $143.8 million, which includes the exercise in full by
the underwriters of their option to purchase up to 390,625 shares of
common stock. KYTHERA estimates the net proceeds from the offering to
be approximately $134.5 million, after deducting underwriting discounts
and commissions and expenses of the offering.

Goldman, Sachs & Co., BofA Merrill Lynch, and Leerink Partners acted as
the joint book-running managers for the offering. Cowen and Company
acted as co-manager.

The offering was made only by means of a prospectus and pursuant to a
shelf registration statement declared effective by the Securities and
Exchange Commission on November 6, 2014. Copies of the final prospectus
and related prospectus supplement relating to the offering may be
obtained by contacting Goldman, Sachs & Co., Attention: Prospectus
Department, 200 West Street, New York, NY 10282, or by telephone at
(866) 471-2526 or e-mail at [email protected]; or BofA Merrill
Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY
10038, or by email at [email protected]com; or Leerink
Partners, Attention: Syndicate Department, One Federal Street, 37th
Floor, Boston, MA 02110, or by phone at (800) 808-7525, ext. 6142, or
by email at [email protected].

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.

About KYTHERA

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization of
novel prescription products for the aesthetic medicine market.
KYTHERA's lead product candidate, ATX-101, is currently in late-stage
clinical development as an injectable treatment for the improvement of
submental fullness, which commonly presents as a double chin, and is a
potential first-in-class submental contouring injectable drug. The FDA
has determined the NDA will have a Prescription Drug User Fee Act
(PDUFA) action date of May 13, 2015. In addition to its lead product
candidate ATX-101, KYTHERA also licensed the worldwide rights to
setipiprant, an early-stage potential treatment for hair loss. KYTHERA
also maintains an active research interest in fat biology, pigmentation
modulation and facial contouring.

Forward-Looking Statements

To the extent that statements contained in this press release are not
descriptions of historical facts regarding KYTHERA, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve substantial risks and uncertainties
that could cause our actual results, performance or achievements to
differ significantly from those expressed or implied by the
forward-looking statements. KYTHERA undertakes no obligation to update
or revise any forward-looking statements. For a further description of
the risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well as
risks relating to the business of the company in general, see the
prospectus supplement and accompanying prospectus for this offering
included on Form 424(b)(5) as part of the Registration Statement on
Form S-3/A filed by KYTHERA on November 6, 2014, as well as KYTHERA's
Annual Report on Form 10-K for the year ended December 31, 2014 and its
other reports filed with the Securities and Exchange Commission.


CONTACT: Investor Contact:
         Heather Rowe
         Director, Investor Relations
         Tel: (818) 587- 4559
         [email protected]
 

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.